Answer
No. It is a targeted bispecific antibody that recruits T cells to kill CD20-positive B cells, although it is still a systemic anticancer treatment with potentially serious adverse effects.
Sources for this answer
- Lunsumio 1 mg and 30 mg concentrate for solution for infusion — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.